KRAS Mutations Reprogram RNA m6A Modifications to Drive CD73-Dependent Immune Evasion in Colorectal Cancer.
It is found that KRAS mutations remodel the N6-methyladenosine (m6A) epitranscriptome to promote immune evasion and highlight METTL3 as a promising therapeutic target.